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ABSTRACT
RNAi-based gene-silencing techniques offer a fast
and cost-effective way of knocking down genes’
functions in an easily regulated manner. Exciting
progress has been made in recent years in the appli-
cation of these techniques in basic biomedical
research and therapeutic development. However,
it remains a difficult task to design effective siRNA
experiments with high efficacy and specificity.
We present siRecords, an extensive database of
mammalian RNAi experiments with consistent effi-
cacy ratings. This database serves two purposes.
First, it provides a large and diverse dataset of
siRNA experiments. This dataset faithfully repre-
sents the general, diverse RNAi experimental prac-
tice, and allows more reliable siRNA design tools to
be developed with the overfitting problem well
curbed. Second, the database helps experimental
RNAi researchers directly by providing them with
the efficacy and other information about the
siRNAs experiments designed and conducted
previously against the genes of their interest. The
current release of siRecords contains the records
of 17192 RNAi experiments targeting 5086 genes.
INTRODUCTION
RNA interference (or RNAi) is a recently discovered,
naturally occurring mechanism for sequence-speciﬁc,
post-transcriptional down-regulation of gene expression
(1). Because RNAi-based gene knockdown techniques
(using siRNAs, or small interfering RNAs) oﬀer a fast
and cost-eﬀective way of disrupting genes’ functions in
an easily regulated manner, rapid progress has been
made in recent years in the application of these techniques
in basic biomedical research and clinical development.
In the basic research domain, siRNAs have become a
standard gene knockdown tool routinely used in molecu-
lar genetics and function genomics laboratories (2,3).
In the clinical domain, several RNAi-based therapies
against ocular diseases (e.g. AMD or age-related macular
degeneration), virus infection (by Hepatitis B and C, and
HIV), cancers (e.g. solid tumors) and inﬂammatory dis-
eases have reached the clinical or pre-clinical trial stage in
development (4–6), and a large number of other RNAi-
based potential therapeutic agents are actively being
explored (7,8).
The successful employment of an RNAi-based gene
knockdown technique depends on the proper design or
selection of the siRNAs, and the adoption of an eﬀective
strategy to deliver the siRNAs to the target cells or tissues
(4,9). The purpose of designing siRNAs is to choose from
a large number of candidate siRNA sites the ones likely to
achieve high potency/eﬃcacy and good speciﬁcity (against
oﬀ-target activity). A properly devised delivery system
(using, e.g. viral or non-viral vectors, conjugates, cationic
liposomes, or complexes with peptides, polymers, antibo-
dies and aptamers) helps to improve the stability of the
siRNA agent, and reduce or eliminate the innate immune
response and/or other harmful side-eﬀects induced by the
siRNA agent (5,7,10).
The issue of how to design siRNAs that produce high
eﬃcacy is the focus of a large body of recent research work
[see recent reviews, e.g. (11–16)]. Since it was discovered
that not all siRNAs are equally potent in their ability to
silence the gene products (17), a series of studies have
pointed to a large number of ‘features’ that might be cor-
related to the higher eﬃcacy of RNAi experiments. These
features can be roughly classiﬁed into three categories.
The ﬁrst category are sequence features, including direct
sequence features which are deﬁned based on the nucleo-
tide identity in particular positions of the siRNA, e.g. the
6th nucleotide of the siRNA sequence is a ‘A’ (18,19), and
sequence-derived features, e.g. the G/C content of the
siRNA is between 30% and 52% (20), and there are no
occurrences of more than three identical nucleotides in
consecutive positions (21,22). The second category include
features deﬁned based on the thermodynamics of the
siRNA, e.g. the binding energy in the n7-n11 region is
between –1.97 and –1.65kcal/mol (23), and features sur-
rounding the concept of siRNA duplex terminal
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the n16–n19 region and n1–n4 region is greater than
1kcal/mol (24). The third category of features are deﬁned
based on the target sites on the mRNA, including target
location-related features, e.g. the target site is outside of
the third quartile of the coding region of the mRNA (25),
and features focusing on the target site accessibility
(26,27), e.g. the local free energy of the most stable struc-
ture is greater than or equal to –20.9kcal/mol (28).
Moreover, recent studies suggested that factors related
to experimental settings, e.g. the types of siRNA con-
structs (29,30), the types of cells used (30–34) as well as
the methods applied in examining gene products (35)
might also inﬂuence the eﬃcacy of the RNAi experiments.
A number of siRNA design tools were established in
which various combinations of these features were imple-
mented [see recent reviews, e.g. (15,36)]. However, the
controversy continues as for which of these features are
truly helpful in selecting high-eﬃcacy siRNAs. Mean-
while, it has been increasingly recognized that many
earlier siRNA design studies suﬀered from the ‘overﬁtting’
problem (14,37,38)—a term commonly used in the
machine learning ﬁeld, referring to situations where, con-
sequent upon excessive training of a classiﬁer, the perfor-
mance of the classiﬁer becomes increasingly better on the
training data, but worsens on testing data. The only prac-
tical way to overcome the overﬁtting problem is to make
use of a large and diverse training dataset (which approx-
imates the ultimate ‘testing data’—the general siRNA
experimental practice as a whole) when investigating fea-
tures or factors associated with the higher siRNA eﬃcacy.
We present siRecords (http://siRecords.umn.edu/si
Records), an extensive database of mammalian RNAi
experiments with consistent eﬃcacy ratings. Because
siRecords hosts the records of all kinds of siRNA experi-
ments conducted with various laboratory techniques and
experimental settings, it is a faithful representation of the
general, diverse siRNA experimental practice. Recently,
using a dataset compiled from siRecords, we analyzed a
large number of reported features for their ability to
improve RNAi eﬀectiveness. Through carefully combining
the most signiﬁcant features, we derived a bundle of
siRNA design rule sets (called the DRM rule sets) which
were subsequently shown to outperform a number of
established siRNA design tools in selecting eﬀective
siRNAs (14). This work demonstrated the usefulness of
the siRecords database.
In this article, we outline the design considerations of
the siRecords database, its structure and features, and
describe the recent improvements made in the siRecords
project.
DATABASE CONTENT
siRecords is designed to serve two diﬀerent purposes: (i) it
provides a large and diverse dataset of experimentally vali-
dated siRNAs with consistent eﬃcacy ratings, and this
dataset can be used by bioinformatics scientists in devel-
oping more reliable siRNA design tools, and (ii) it helps
experimental RNAi researchers directly by providing the
information about what siRNAs have been tested by other
researchers against the genes of their interest, and what
eﬃcacy levels were achieved in those previous RNAi
experiments.
The literature curation and data recording procedures
have remained unchanged over the past four years. First,
queries are sent to the PubMed database (http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed)
for publications related to ‘RNAi’ and ‘siRNA’. Then, the
abstracts of the publications are screened, and the full text
articles likely to contain information about RNAi gene
silencing experiments are retrieved and further examined.
Next, for each article containing descriptions of RNAi
experiments, the siRNA sequences, the target genes and
other key information about experimental conditions are
recorded. This information includes: the cells or tissues in
which the RNAi experiments were conducted, the forms
of the siRNA agents—chemically synthesized oligos or
vector transfected shRNAs, and the methods applied in
testing the eﬃcacy of the siRNAs—western blot, RT–PCR
or others. The siRNA sequences are aligned with the
mRNA sequences of the target genes using bl2seq
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi),
and the aligned sequences are recorded.
Moreover, an eﬃcacy rating is assigned to each RNAi
experiment, based on the description about the result of
the gene silencing experiment made in the article. The
eﬃcacy rating scheme was designed with balanced consid-
erations. A very coarse-grained rating scheme (for exam-
ple, a binary scheme that rates siRNAs with ‘eﬀective’ and
‘ineﬀective’) would result in poor usefulness of the data-
base because of the limited information it provides. On the
other hand, a very ﬁne-grained rating scheme (for exam-
ple, one that classiﬁes siRNAs into 10 eﬃcacy categories)
would lead to diﬃculty in obtaining accurate ratings,
resulting in a less reliable database being produced. We
balanced these two factors and chose to use a four-level
rating scheme, where the eﬃcacy of an RNAi experiment
is rated as ‘very high’ if the gene product is reduced by
more than 90%; it is rated as ‘high’ if the gene product is
reduced by 70–90%; ‘medium’ if between 50% and 70%
of gene knockdown is achieved; and ‘low’ if less than 50%
of gene knockdown is obtained. The informative sentences
in the original articles describing the siRNA eﬃcacy are
copied down and stored in the ‘original_assessment’ ﬁeld
in the database. When adequate textual descriptions about
the siRNA eﬃcacy are not available, best eﬀorts are made
to assign the eﬃcacy rating scores based on the ﬁgures (gel
images or summary bar-graphs) presented in the articles,
and this information (the basis of the eﬃcacy score assign-
ment) is also kept in the ‘original_assessment’ ﬁeld in the
database.
During the data deposition process, the siRNA
sequence that is maintained in the database may undergo
some transformations from the original publication into
the database. First, it is possible that DNA bases from the
published resource are deposited as RNA, one or more
bases represented as ‘T’ may be transformed into ‘U’.
Second, it is possible that the sense strand or passenger
strand of the siRNA sequence is deposited rather than the
guide strand. These are known issues that are being
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neous as to whether these transformations have occurred
or have been corrected. Future releases of siRecords will
contain estimates of the degree to which we believe the
contents are clean or contain speciﬁc kinds of contaminat-
ing or transformed data.
There are four major tables in the database schema:
SiRecord, which stores the siRNA sequence, key experi-
mental conditions (cell or tissue type, host species, method
of making/delivery siRNAs, method of testing eﬃcacy and
the test object), original eﬃcacy assessment (sentences
related to eﬃcacy assessment in the original articles),
and the eﬃcacy rating assigned by siRecords curator;
Gene, which stores information about the genes targeted
by the siRNAs, including Genbank accession, organism
and description of the gene; Correspondent, which stores
the contact information of the siRNA origin; and
Publication, which stores key information, including
PubMed ID and citation data of the original publication.
The current release of siRecords hosts the records of
17192 RNAi experiments targeting 5086 unique genes,
curated from 6122 research articles. The size of the data-
base has more than quadrupled when compared to the
ﬁrst release of the database (Figure 1).
The web interface of the database has recently been
rewritten. The improved interface includes a ‘siRNA
Input Wizard’ which will guide data contributors to
submit their own records of RNAi experiments with
ease. Moreover, the primitive siRNA design tool incorpo-
rated in the previous release of siRecords has been
replaced by siDRM—a recently developed full-featured
siRNA design program in which updated DRM rule sets
are implemented (39).
UTILITY
siRecords can be accessed at http://siRecords.umn.edu/
siRecords/. At the main page, the user could query a
gene by entering the Genbank accession number or GI
number, and the matching records would be presented
to the user. After the user selects a record, the record dis-
play page will present with all relevant information about
the record, including the siRNA sequence, experimental
setting, eﬃcacy rating and the source of the record. The
links to all other records targeting the same gene, and all
other records obtained from the same source is displayed.
Data contributors could submit their own records of
RNAi experiments with the help of the ‘siRNA Input
Wizard’ shown in the left panel of the web site (registra-
tion is required).
DATA ACCESS
The siRecords web site is publically accessible through
the URL http://siRecords.umn.edu/siRecords. Academic
users can obtain a copy of the current release of the data-
set by sending an email to siRecords@biocompute.
umn.edu.
IMPLEMENTATION
The siRecords database is a relational database implemen-
ted with MySQL on a Fedora II Linux system running on
an Intel DUO core 2 computer. The front-end web inter-
face is implemented as a PHP project running under
Apache 2.0.
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Figure 1. Statistics summary of the records of RNAi experiments in the current release of siRecords. (a) Species distribution. The category ‘monkeys’
includes multiple species, including Aotus trivirgatus, Cercopithecus aethiops and Macca mulatta.( b) Eﬃcacy rating distribution. (c) Distribution of
the siRNA lengths. (d) Distribution of the methods by which the siRNAs are produced and delivered.
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